e-Drug3D

2191

ORFORGLIPRON

INN
ORFORGLIPRON

cas 2212020-52-3

CLASS

METABOLISM
A GLP-1 RECEPTOR AGONIST

ROUTE (list)

ORAL

ATC code

PK parameters

F 77 PERCENT
VD 285 LITER
Cl 7.15 LITER / HOUR
PPB 99 PERCENT
t1/2 39 HOUR

Solubility

INSOLUBLE IN WATER

Target

TARGET GLP-1 RECEPTOR

DrugCentral

Download SDF file

1,2,4-Oxadiazol-5(2H)-one, 3-[(1S,2S)-1-[2-[[(4S)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methyl-1H-indazol-5-yl)-2,3-dihydro-2-oxo-1H-imidazol-1-yl]-2,4,6,7-tetrahydro-4-methyl-5H-pyrazolo[4,3-c]pyridin-5-yl]carbonyl]-5-[(4S)-tetrahydro-2,2-dimethyl-2H-pyran-4-yl]-1H-indol-1-yl]-2-methylcyclopropyl]-

Formula:
C48H48F2N10O5

Calculated chemical properties:

MW 882.96
NB_atoms 65
XLogP 7.44
PSA 137.686
NB_HD 1
NB_HA 15
fsp3 0.38
Lipinski(0=no;1=yes) 0

FDA
NDA 220934 (label) INN (ORFORGLIPRON CALCIUM) FOUNDAYO (ELI LILLY AND CO) APPROVAL= AP YEAR= 2026 NEWMOLECULARENTITY